Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B

• Published in: Journal of viral hepatitis Vol. 10; no. 4; pp. 298 - 305
• Main Authors: Cooksley, W G E, Piratvisuth, T, Lee, S-D, Mahachai, V, Chao, Y-C, Tanwandee, T, Chutaputti, A, Chang, W Yu, Zahm, F E, Pluck, N
• Format: Journal Article
• Language: English
• Published: England 01.07.2003
• Subjects: Adolescent; Adult; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis B e Antigens - immunology; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - immunology; Humans; Injections, Subcutaneous; Interferon-alpha - administration & dosage; Interferon-alpha - adverse effects; Male; Middle Aged; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - adverse effects; Recombinant Proteins; Reference Values; Risk Assessment; Serologic Tests; Treatment Outcome

Current therapies for chronic hepatitis B (CHB) have a number of limitations, and better treatment options are needed. Peginterferon alpha-2a (40 kDa) is superior to conventional interferon alpha-2a in the treatment of chronic hepatitis C. This is the first report on peginterferon alpha-2a (40 kDa)...